US Infant Formula Safety Questions Don’t Include Cronobacter National Reportable Disease Listing
FDA submitted four questions for USDA committee's advice on strengthening prevention of cronobactera contaminations such as problem leading to Abbott facility shutdown earlier in 2022 and supply shortage still affecting US. "High mortality rate of infants infected with cronobacter sakazakii should be enough for consumers expect this issue to receive an urgent response,” Stop Foodborne Illness CEO Mitzi Baum tells FDA and USDA.
You may also be interested in...
Threat Of Cronobacter Contamination For Powder Infant Formula Rings Clear In Latest US Recall
Reckitt's identification of Cronobacter sakazakii as contaminant in its 145,000-can Enfamil recall is latest clear statement about Cronobacter bacteria potentially disrupting supply of formula and other nutritionals distributed in powder form.
Perrigo Supports Hypoallergenic Infant Formula Savings Claims, Not Equivalence To Enfamil Brand
Perrigo can continue claiming its store brand hypoallergenic infant formula saves customers more than 20% compared to leading name brands while providing similar nutrition to leading brands. But meeting AAP standard doesn’t measure up as equivalent to brands, industry self-regulation group says.
US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”